Targeting mitochondrial ion channels for cancer therapy

Ildiko Szabo a, b, *, Mario Zoratti b, Lucia Biasutto b, c

a Department of Biology, University of Padova, Italy
b CNR Institute of Neurosciences, Padova, Italy
c Department of Biomedical Sciences, University of Padova, Italy

ARTICLE INFO

Keywords:
Mitochondria
Ion channels
Drug targeting
Channel interactions

ABSTRACT

Pharmacological targeting of mitochondrial ion channels is emerging as a promising approach to eliminate cancer cells; as most of these channels are differentially expressed and/or regulated in cancer cells in comparison to healthy ones, this strategy may selectively eliminate the former. Perturbation of ion fluxes across the outer and inner membranes is linked to alterations of redox state, membrane potential and bioenergetic efficiency. This leads to indirect modulation of oxidative phosphorylation, which is/may be fundamental for both cancer and cancer stem cell survival. Furthermore, given the crucial contribution of mitochondria to intrinsic apoptosis, modulation of their ion channels leading to cytochrome c release may be of great advantage in case of resistance to drugs triggering apoptotic events upstream of the mitochondrial phase. In the present review, we give an overview of the known mitochondrial ion channels and of their modulators capable of killing cancer cells. In addition, we discuss state-of-the-art strategies using mitochondriotropic drugs or peptide-based approaches allowing a more efficient and selective targeting of mitochondrial ion channel-linked events.

1. Introduction

Mitochondrial involvement in cancer physiology is multi-faceted (reviews e.g. Refs. [1–5]). All other aspects aside, these organelles have a number of tightly regulated ion channels in both the outer and inner membranes [6]. These pores are emerging as important oncological targets, since their pharmacological modulation may directly affect the release of cytochrome c, which is the point of no return during mitochondrial apoptosis. Many chemotherapeutic drugs trigger programmed cell death by inducing damage to DNA and subsequent activation of p53-dependent pathways that lead to migration of pro-apoptotic Bcl-2 family members to the outer mitochondrial membrane (MOM) and subsequent MOM permeabilization (MOMP) leading to cytochrome c release from the mitochondrial inter-membrane space. By acting on mitochondrial channels, especially on those of the inner membrane (MIM), it is possible to bypass p53-related events. This is of great importance, since many types of cancer develop chemoresistance due to mutations in p53 and/or upregulation of anti-apoptotic proteins or downregulation of pro-apoptotic proteins. MOM channels were shown to play a crucial role for MOMP, via hetero-oligomerization with pro-apoptotic Bax and Bak or anti-apoptotic Bcl-2 [7,8], while MIM ion channels modulate sensitivity to apoptotic stimuli by affecting the mitochondrial membrane potential. An alteration of the MIM potential (Δψ) (around −180 mV) changes the driving force for calcium entry into the matrix: above a critical threshold, the matrix-accumulated calcium triggers opening of the so-called mitochondrial permeability transition pore (MPTP) and this leads to swelling of the organelle, rupture of the MOM and release of pro-apoptotic factors from the inter-membrane space.

MPTP opening can be aided also by oxidative stress, which develops as a consequence of either depolarization or hyperpolarization of the MIM [9]. Mitochondria constitute the redox hub of any cell, and the major source of the reactive oxygen species (ROS) which play such diverse and fundamental roles in cancer (e.g.: revs [1,10,11]). Many “mitocans”, i.e. compounds that contrast cancer by acting on mitochondria [12–15], kill cancerous cells because they elicit a ROS production incompatible with the cell’s survival (for reviews see e.g. Refs. [12,14,16,17]). Cancerous cells are especially sensitive to hyper-generation of ROS because they are under oxidative stress to start with [18,19], and this strategy is achieving practical relevance in the clinic (e.g. Refs. [20,21]).

For the above reasons, over the past few decades, more and more groups have focused on the pharmacological targeting of MPTP but also of other channels, whose modulation may trigger cytochrome c release.
from mitochondria and/or promote other types of cell death.

While many membrane-permeant drugs acting on mitochondrial channels have been identified over the last years, their proceeding into the clinic is hampered by two main drawbacks: first, many of the MOM and MIM ion channels have multiple localizations within the cells, so the cellular effect cannot be reliably ascribed to the action of the drug on the mitochondrial channel only; second, for many of the channel modulators possible side effects have not been taken into account and their specificity toward cancer cells has not been proven. These difficulties can, a priori, be overcome by using mitochondria-targeted so-called mitochondriotropic drugs and/or specific peptides interacting with the mitochondrial channel. This strategy may also reduce the dose required to exert beneficial effects, therefore likely reducing side-effects.

The present review gives a brief overview of mitochondrial channels and highlights the most promising channel modulator drugs, focusing on those tested also in vivo, and briefly describes the above-mentioned strategies possibly leading to enhanced specificity and efficacy.

2. Mitochondrial ion channels and their pharmacological targeting by small molecules

2.1. Mitochondrial permeability transition pore as a key protagonist in cell death

Arguably, the oncologically most relevant mitochondrial channel may be considered to be the mitochondrial permeability transition pore (MPTP), a large, unselective channel forming in the MOM of mitochondria stressed by excessive ROS and Ca\(^{2+}\), whose activation precipitates cell death (recent reviews: [22–25]). This pore is one of the largest present in any biological membrane, having an estimated equivalent diameter of 2–3 nm when fully open (reviewed in Ref. [26]). The mean diameters of VDAC1 (mitochondrial porin), bacterial porin OmpC and α-hemolysin, for comparison, have been estimated – using similar methods based on solute permeation – at about 1.1, 0.8 and 0.3 nm, respectively [27]. Despite this large size, allowing traffic of molecules with a molecular weight up to 1500 Da, transient openings of MPTP seem to occur under physiological conditions and to be relevant in physiological Ca\(^{2+}\) homeostasis in different experimental settings such as ischemic preconditioning or somatic cell re-programming [28–30]. When the MPTP is open for a longer (seconds) time, it causes permanent MIM depolarization, interruption of ATP synthesis, matrix swelling, MOM rupture and, as a consequence, release of pro-apoptotic proteins from the intermembrane space (see e.g. Refs. [26,31]). Because of this crucial contribution to cell death, the importance of inducing long-lasting openings of MPTP in cancer cells became soon evident. It has been argued that cancer cells are desensitized to stimuli leading to the permeability transition [32,33]. Drugs or conditions causing its sustained opening in cancerous cells (only) would thus represent a potentially very valuable addition to the oncologists’ arsenal.

Several compounds have been identified which appear to directly inhibit the MPTP through its (putative) components [34–36]. Since they act as repressors, they may be more useful in other contexts in which the MPTP plays a role, e.g. ischemic injury. The same holds for the long-known MPTP inhibitor acting through the modulatory component Cyclophilin D, i.e., Cyclosporin A (CSA) [37,38].

Many drugs and natural substances have on the other hand been identified as openers of MPTP, on the basis of their ability to induce, at least in vitro, mitochondrial swelling, a process that can be easily detected by a spectrophotometer. Most of these molecules, with variable chemical structures, were tested also on cancer cells to assess their ability to trigger various forms of cell death. The question arises of how dozens of dissimilar molecules (for recent reviews and lists see Refs. [39–41]) can activate MPTP opening. Pore activation is known to be favoured by MOM depolarization, high ROS levels and matrix Ca\(^{2+}\) overload, while its inhibition can be achieved by acidic matrix pH, various divalent cations and Mg\(^{2+}/\text{ATP(ADP)}\) and by the high-affinity inhibitor cyclosporine A. The identity of the MPTP is still debated (see, e.g. Refs. [25,41]), but after intensive research and several different hypotheses, the scientific community is finding a consensus on the proposal that the ATP–producing enzyme FoF1 ATP synthase may give rise to MPTP channel activity under specific conditions [42–45]. In particular, a recent structural study identified subunit e, connected to a lipid plug within the c-ring, as the one whose retraction may lead to a gradual disassembly of the c-ring, suggesting pore formation by distanced c subunits [46]. If this model turns out to be correct, the action of a large spectrum of molecules might converge on subunits e or c of this enzyme, so important for life. However, an indirect action of the different molecules on MPTP opening cannot be excluded: as a matter of fact, for most molecules that induce the permeability transition in swelling assays, no information is available at the single channel level in patch clamp experiments. Indeed, as mentioned above, beside calcium and ROS, no other agents are known to directly trigger MPTP opening. Thus, most of the compounds that lead to opening of this pore probably do it indirectly, by triggering ROS release, calcium overload in the mitochondrial matrix or strong membrane depolarization (Fig. 1). One example is provided by AUL12, a Gold(III)-dithiocarbamate complex which inhibits Complex I of the mitochondrial respiratory chain, causes production of ROS and thereby activates mitochondrial kinase GSK3-α/β which promotes opening of the MPTP [47,48].

Despite the identification of a number of compounds acting indirectly on MPTP, only few studies have provided in vivo evidence for the usefulness of such a strategy and reached the clinical trial stage. One of the best-investigated drugs is the triterpenoid betulinic acid, which, among many other cellular effects, triggers ROS production and induces CSA-sensitive cytochrome c release via MPTP, even in Bax/Bak-deficient cells. Betulinic acid is highly efficient against tumor cells of different origins as well as against tumor cells that are resistant to other, classical chemotherapeutic agents. It spares instead untransformed cells [49] (for recent review see Ref. [50]). Interestingly, betulinic acid has recently been shown to inhibit voltage-gated calcium channels [51], however whether it acts analogously on mitochondrial calcium channels is still unknown. This drug shows a satisfactory selectivity index for pathological versus healthy cells even at high doses and is effective, at least in vitro, against many types of cancer including melanoma, cancers of the gastrointestinal tract, pancreatic cancer, myeloid leukemia, with IC\(_{50}\) values ranging between 1 and 13.0 µg/mL [52]. Due also to early recognition - it was shown to be effective against melanoma in mice, without causing adverse effects, in 1995 [53] - this compound entered phase I and II clinical trials against dysplastic nevi, which can develop into melanoma. Unfortunately, the trial was stopped due to funding issues (ClinicalTrials.gov).

Another promising drug acting via MPTP is noscapine, an opium phthalide isouquinoline alkaloid that shows no toxicity in animals and humans and was recently employed in two clinical trials on refractory multiple myeloma and on chemo-resistant chronic lymphocytic leukemia. This agent was recently shown to induce apoptosis in chemo-resistant colon cancer cells in vitro [54], by causing mitochondrial membrane depolarization, through a still-undefined mechanism, ultimately leading to MPTP opening. It was tested in two clinical trials against myeloma and low-grade non-Hodgkin’s lymphoma, terminated because of lack of response and funding problems, respectively (ClinicalTrials.gov). A similar mechanism of action was proposed for Amorfrutin C, isolated from indigo bush, which reduced proliferation of different types of cancer cells such as colon cancer and breast cancer [55]. This drug however has not entered the clinical phase yet.

Honokiol, from magnolia, is another example of a drug able to induce death of a variety of cancer cells by triggering MPTP opening and to overcome Bcl-2 and Bcl-XL-mediated apoptotic resistance. Honokiol, like Amorfrutin B, activates PPARy (peroxisome proliferator-activated receptor gamma). It was shown to efficiently kill apoptosis-resistant B-cell chronic lymphocytic leukemia (B-CLL) cells as well as cells from chemoresistant multiple myeloma patients [56]. Together with other
active compounds, it is currently in clinical trial for testing against papilloma virus-linked cervical lesions.

Plant-derived hirsutine has recently been shown to exert anti-cancer activity in a lung cancer xenograft mouse model. It acts through a signalling cascade leading to GSK3β dephosphorylation and MPTP opening [57]. GSK3β was shown to modulate activity of the MPTP-regulatory component, cyclophilin (CyP) D, a matrix chaperone that favors pore opening [58]. Importantly, hirsutine in vivo was not toxic for normal tissues.

2.2. Mitochondrial calcium transport systems allow matrix calcium overload that triggers MPTP opening

For most cell types, addition of 50–100 μM Ca²⁺ to isolated mitochondria is sufficient to induce MPTP opening in both swelling assays and patch clamp experiments. Such a high concentration can be reached in the mitochondrial matrix (where generally it is about 10 μM) by activation of entry pathways or block of exit routes for Ca²⁺. Calcium uptake into mitochondria takes place prevalentantly through the mitochondrial calcium uniporter complex (MCU) [59–64], although other calcium channels were also found to be active in the MIM. In particular, current candidates include the transient receptor potential TRPC3 [65] and vanilloid type1 (TRPV1) [66] channels and the mitochondrial ryanodine receptor (mRyR1) [67,68]. Calcium exit instead is mediated prevalently by NCLX, the mitochondrial Ca²⁺/Na⁺ antiporter [69].

MCU and TRP calcium-permeable channels show different expression levels in healthy cells compared to various types of cancer cells (for recent reviews see Refs. [70–72]). TRPC3 is specifically inhibited by Pyr3 (Ethyl-1-(4-(2,3,3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate), which has been shown to depolarize the MIM and boost ROS production when applied together with dexamethasone [73]. In the case of TRPV1, a recent study linked apoptosis induction by capsacin to mitochondrial calcium overload, although whether mitochondrial TRPV1 is responsible for the effect of this channel agonist has not been specifically addressed [74]. As to MCU, a small heterocyclic compound, AG311, (5-{(4-methylphenyl)thio}-9-H-pyrimido[4,5-b]indole-2,4-diamine) was shown to depolarize mitochondria and proposed to exert its tumor growth-retarding effect by activating MCU [75]. However, the same group identified in their subsequent work complex I of the respiratory chain as the target of AG311. In any case, the drug was not able to reduce the growth of breast cancer in a murine orthotopic xenograft model when applied alone [76]. A further candidate to activate MCU is kaempferol, a plant flavonoid, observed in a few studies to increase mitochondrial calcium uptake [77–79]. However, caution must be exerted and proof of direct channel activation would be welcome, especially since this agent inhibits other channels, e.g. TRPC5 [80], and activates the large conductance calcium-dependent K⁺ channel [81], which also has a mitochondrial counterpart.

In addition to direct activation of the pore-forming component of MCU, one valid possibility would be that of modulating the activity of its regulators, including the EF-hand calcium binding proteins MICU1 and MICU2, widely expressed in different tissues. Recent structural data suggest that the MICU1-MICU2 dimer blocks the channel pore at low cytosolic Ca²⁺ concentrations, while at increasing concentrations the dimer detaches from the complex [82]. Thus, any molecule detaching this dimer from MCU may facilitate calcium overload. To our knowledge such a compound has not been identified yet. On the other hand, recent data provide evidence that MICU1 potentiates MCU activity by increasing the channel’s open probability when cytosolic Ca²⁺ binds to the EF hands [83,84]. 1 mM spermine was also reported to activate MCU channel [85], but to our knowledge no studies employing genetic deletion of MCU addressed the question of whether apoptosis of cancer cells can be triggered by spermine via its action on MCU. It has been suggested instead that oxidative deamination of spermine might produce ROS and consequent MPTP opening [86].

Matrix calcium is known to be required for the correct metabolism of mitochondria [87]. Interestingly, a recent work provided evidence that in the presence of the MPTP inhibitor CSA, MCU activity promotes cancer cell proliferation [88]. Upregulation of MCU expression contributes to ROS production and cancer cell migration [89–91]. Therefore, since MPTP opening is often prevented by specific signalling pathways in cancer cells, block of MCU might be a strategy in the case of cells that are resistant to MPTP inducers. In this respect, the recent discoveries of a specific MCU inhibitor, mitoxantrone [92], and of a membrane-permeant inhibitory Ruthenium complex named Ru265 [93] as well as of MICU1 modulators MCU-14 and MCU-11 [94] (for a recent review see Ref. [95]) may be of relevance, even if they have not yet been applied in the context of cancer (mitoxantrone however was developed as an anti-cancer agent and is/has been tested as such in several clinical trials). A compound named DS16570511 has also been proposed as MCU inhibitor, but its ability to directly block the channel has not been demonstrated [96]. As pointed out by Hajnoczky and colleagues [95], these inhibitors, except MCU11, are expected to be toxic for healthy cells as well, since they depolarize the mitochondrial membrane and cause side effects. A further inhibitor, KB-R7943, may be taken into consideration, since it has recently been shown to alleviate P. aeruginosa–triggered inflammatory responses in vivo [97], and it may have a similar anti-inflammatory effect in the tumor micro-environment, therefore negatively affecting tumor growth. However, this drug is also a potent inhibitor of the plasma membrane (PM) Na⁺/Ca²⁺ exchanger NCX1 [98] (contra [99]) and its tumor-reducing action observed in a murine prostate xenograft model has been ascribed to its effect on the PM exchanger [100] rather than to inhibition of the mitochondrial channel.

Ca²⁺ exit from the matrix through MIM-located NCLX can be blocked by the benzodiazepine CGP37157 [69,101]. Surprisingly, a lack of mitochondrial calcium overload and a protective effect were observed in models of neuronal injury using this drug, apparently due to its ability to block voltage-dependent calcium channels of the plasma membrane as well [102]. On the other hand, genetic deletion of NCLX in brown adipose tissue led to calcium overload upon adrenergic stimulation and to the opening of the permeability transition pore [103]. This finding is in accordance with previous studies showing that CGP37157 enhanced the sensitivity of cancer cells to TRAIL-induced death [104,105].
2.3. Voltage-dependent anion channels as a pathway in the MOM for metabolite and calcium entry

VDAC1 and VDAC2, the two major isoforms of mitochondrial porin [106], are involved in cell death in various ways. For example, VDAC1 plays a role in matrix Ca\(^{2+}\) overload, since it provides the Ca\(^{2+}\)-permeable pathway in the MOM [8,107]. VDAC1 can oligomerize in a Ca\(^{2+}\)-dependent process involving its N-terminus. These oligomers are seemingly implicated in the release of pro-apoptotic factors such as apoptosis-inducing factor (AIF) and cytochrome c [108]. VDAC1 as well as VDAC2 regulate cell death also by interacting with anti-apoptotic members of the Bcl-2 family contributing to MOM permeabilization [109,110], while interaction of VDAC1 with hexokinase (HK) is instrumental for cancer cell survival [108,111]. In addition, VDAC3, capable of sensing the oxidative state in the mitochondrial inter-membrane space [112], is emerging as potential marker for disease (for review see Ref. [113]). VDAC1 and VDAC3 can also interact with anti-apoptotic Mcl-1, promoting release of ROS and calcium transfer into the matrix, which in turn enhance migration [114]. In summary, VDAC isoforms contribute to cancer cell progression in different ways (for recent review see Ref. [115]). However, while many drugs affecting VDAC1 have been identified, those specifically acting on the other isoforms are less investigated. A recent work identified WEHI-9625, a novel tricyclic sulfone small molecule, that was able to bind to VDAC2 and inhibit Bak-triggered apoptosis [116], suggesting that an activator rather than an inhibitor of VDAC2 would be useful to eliminate cancer cells.

Compounds that decrease the conductance (i.e., the slope of the current/voltage relationship; roughly reflecting in this case the permeability of the water-admitting channel) of VDAC1 (Fig. 2) were instead shown to exert a selective pro-apoptotic and cytotoxic activity against cancer cells. For example, cytharin-R, a cythatherepenoid, decreases channel conductance as well as cancer growth in vivo, by promoting apoptosis even in Bax/Bak-deficient cells [117]. In addition, Cytharin-R promoted VDAC1 oligomerization, that was linked to apoptosis induction, since VDAC1-interacting molecules such as DIDS and its analogs (H\(_2\)DIDS, STS, DPC), which reduce VDAC1 oligomerization, inhibited cell death [118]. Avicins, a class of plant stress-induced triterpenoid metabolites, also displayed anti-cancer and anti-inflammatory properties (see e.g. Refs. [119,120]). Avicins however, in addition to VDAC1, target various proteins, such as tubulin and topoisomerase. They trigger cytochrome c release by inhibiting respiration and by reducing the efficiency of antioxidant systems, leading to enhanced oxidative stress. Another class of drugs that could be of value for the treatment and/or prevention of malignancy are cannabinoids (CBD), which block VDAC1 activity and exhibit strong in vitro anti-tumor effects against numerous cancer cells types [121,122]. Curcumin has also been shown to affect VDAC1 function by interacting with its N-terminal domain [123]. Likewise, the N-terminal part of VDAC can be targeted also by the bioactive components of the herb Rheum officinale Baill, capable of inducing apoptosis in many tumoral cell lines [124]. While many studies addressed the effect of the above drugs in cell lines or xenografts, only few investigated Hortonoptopic models. Among all these drugs modulating VDAC activity, only curcumin entered the clinical phase and is under investigation either alone or in combination for various diseases, including invasive breast cancer and non-small cell lung cancer (clinical trial.gov). A clinical trial involving cannabidiol in biochemically recurrent prostate cancer has just been launched (NCT04428203).

2.4. Mitochondrial potassium channels as regulators of membrane potential and ROS release

Surprisingly, in various tissues the mitochondrial inner membrane was demonstrated to host several types of potassium channels. All of them, except the ATP-dependent potassium channel, have multiple localizations within the cells. In most cases the mitochondrial channels show pharmacological and biophysical properties indistinguishable from those of the counterparts located in the PM [6]. The question arises of what physiological relevance can be ascribed to the observed potassium channel redundancy in the MIM. One plausible explanation is that the presence of different channels, regulated by diverse intracellular factors, may offer a stimulus-dependent fine-tuning of mitochondrial function. In fact, some of the MIM K\(^{+}\) channels, such as Kv1.3 [125], Kv1.5 [126] and Kv7.4 [127] are classical voltage-dependent channels, while another class of MIM channels are triggered by calcium: these are the small- [128], intermediate- [129], and big- [130] conductance calcium-activated potassium channels (referred to as SKCa, IKCa and BKCa, respectively). Still another channel is the one gated by ATP and therefore named mitoKATP (see e.g. Refs. [131–134]). The two-pore channel TASK-3 is sensitive to acidic pH [135,136]. In addition, MIM harbours the sodium-activated potassium channel mitoSLO2 [137]. Recent proteomic and biochemical data suggest that the hyperpolarization-activated cationic HCN3 functions as K\(^{+}\) channel in kidney mitochondria [138]. Finally, a splicing isoform of the renal medullary K\(^{+}\) channel ROMK2 has been shown to contribute to mitoKATP activity, at least in some tissues [133,134].

Regardless of the molecular nature of the MIM potassium channels, they have all been linked to the regulation of mitochondrial membrane potential (\(\Delta \Psi\)), as flux of potassium ions driven by the electrochemical gradient into the matrix leads to depolarization and, viceversa, block of these channels leads to hyperpolarization. As a consequence, \(\Delta \Psi\) and calcium influx may also be modulated by K\(^{+}\) channel activation or inhibition. In addition, matrix volume is affected by K\(^{+}\) channels, such as Kv1.3 [125], which determine spatial acidification of the matrix, that in turn affect mitochondria bioenergetic state. For these reasons, K\(^{+}\) channel modulation may represent a potential therapeutic target in cancer cells.
channel (mitoKv1.3) [125], which had been found to be involved in cell death mediated by Bax [143]. The mechanism envisioned involves “plugging” of the channel vestibule by a specific, positively charged amino acid residue of Bax (K128) once the pro-apoptotic protein has inserted into the MOM [144] (Fig. 3A). This interaction mimics that of peptide blockers of Kv pores. In fact, treating isolated mitochondria with Bax, with the peptide toxin inhibitors Margatoxin (MgTx), ShK, or with Psora-4 produced the same phenomena: a transient hyperpolarization of the MIM (attributed to block of the channel-mediated depolarizing K⁺ uptake), a marked production of ROS, consequent activation of the MPTP, and cytochrome c release [143]. Expression of Kv1.3 was found to correlate with sensitivity to chemotherapy in a number of cancer cell lines [145], and PAP-1, Psora-4 and clofazimine - the latter another permeant inhibitor of the channel - turned out to induce apoptosis, acting in a sense like a pharmacological stand-in for Bax. Please note that MgTx and ShK, two membrane-impermeant Kv1.3 blockers, do not affect cell survival or mitochondrial physiology when added to intact cells (Fig. 3B). Clofazimine [146], a drug used in the clinic and exerting also various Kv1.3-independent effects [147], was tested in vivo and found to significantly reduce melanoma and pancreatic ductal adenocarcinoma (PDAC) in murine orthotopic tumor models [148,149]. Silencing of the channel prevented the apoptosis-inducing effect of the three drugs, indicating that Kv1.3-dependent pathways are involved.

Among the other MIM K⁺ channels, mitochondrial IKCa is of interest in the context of cancer, since its membrane-permeant inhibitors TRAM-34 and clotrimazole regulate oxidative phosphorylation in PDAC cells [150] and sensitize melanoma cells to apoptotic stimuli, by triggering release of mitochondrial ROS [151]. Likewise, changes of mitoTASK-3 expression/functionality have been linked to alterations of mitochondrial bioenergetics and morphology [152]. However, there is no clear evidence that targeting the mitochondrial channel is relevant for apoptosis induction, since no systematic studies have been carried out comparing the effect of membrane-impermeant and membrane-permeant inhibitors. In addition, recent evidence raises the possibility that even modulation of PM channels might affect mitochondrial ROS production and morphology [153] or mitochondrial membrane potential [154] by still unclarified mechanisms. In particular, Pardo and colleagues observed that lack or inhibition of the Kv10.1 channel of the PM by a membrane-impermeant specific antibody induced mitochondrial fragmentation and ROS production [153], while

---

Fig. 3. Role of the voltage-dependent potassium channel Kv1.3 and its pharmacological modulation in cell death. A) The mitochondrial counterpart of the plasmamembrane-located Kv1.3 channel (mtKv1.3) can be blocked by membrane-inserted Bax, through the specific K128 residue. The block of channel activity causes an initial hyperpolarization followed by ROS release and MPTP opening. B) Membrane-impermeant toxin inhibitors of Kv1.3 capable of reaching only the plasma-membrane-located Kv1.3 are unable to trigger cell death, indicating that mtKv1.3 is the channel whose function is relevant for apoptosis. C) Membrane-permeant, mitochondriotropic inhibitors PAPTP and PCARBTP (indicated as PCARB) efficiently trigger the same series of events shown in A), leading to cell death of cancer cells in vitro and in orthotopic tumor models. D) The more soluble derivative of the small molecule inhibitor of Kv1.3 (and of mtKv1.3) PAP-1, named PAP-1-MHEG promotes ROS production by acting on mtKv1.3 that is strictly interacting with the respiratory chain complex I, thereby amplifying the ROS-producing effect of the drug that may transfer electrons from complex I to oxygen. The See text (par. 2.4 and 3.2) for details.
in the other work block of the ASIC1a acid-sensitive channel with membrane-impermeant Psalmotoxin-1 blocked mitochondrial Ca$^{2+}$ signals [154].

Altogether, MIM K$^+$ channels remain excellent oncological targets. However, due to i) multiple localization of these proteins within the cell; ii) lack of mitoK$^+$ channel-specific K$^+$ channel inhibitors; iii) the observation that PM-located K$^+$ channels may also affect mitochondrial fitness; iv) the often-observed off-target effects of many inhibitors [139], caution has to be taken when interpreting the effect of K$^+$ channel modulators on cell survival/death. In particular, it would be desirable to assess in each case the cellular effects of channel-modulating drugs in isogenic systems either expressing or lacking the channel protein.

2.5. Anion channels of the inner membrane – a further way to regulate ROS and MPTP opening?

Several members of the Chloride Intracellular Channel (CLIC) family have been located at mitochondria. CLICs are emerging as biomarkers in several diseases (for review see Ref. [155]) including cancer [155,156]. In electrophysiological recordings using artificial bilayer membranes, CLICs form redox- and pH-sensitive channels. While CLIC4 is located in the MOM, CLIC1 [157] and CLICS [158] were found in the MIM, also by patch clamp. CLICs, the first CLIC identified in the MIM, was shown to regulate the production of mitochondrial ROS by respiratory chain complexes, thus in principle CLICs modulators could also be exploited for cancer treatment. Indeed, high expression of CLIC1 was correlated with high ROS production. The other way around, inhibition of CLIC1 reduced ROS release and migration of gastric cancer cells [159]. On the other hand, the absence of CLICS specifically in cardiac mitochondria increased ROS release [158]. Interestingly, the connection between ROS production and CLICs as well as the above-mentioned channels may also be relevant in inflammation [160].

CLICs are inhibited by indanyloxyacetic acid-94 (IAA-94), but this is not a specific drug for this subset of channels, since IAA-94 inhibits also, e.g., the volume-regulated chloride channels of the plasma membrane [161]. In addition, mitochondrial CLIC family members are present also in several other intracellular membranes [155]. Therefore, more work is needed to identify mitochondrial CLIC-specific modulators.

3. Mitochondriotropic drugs

3.1. Chemical modification strategies of anti-cancer drugs to target them to mitochondria

With the (current) exceptions of MCUC and the K(ATP) channel recently identified by Paggio et al. [132], all known mitochondrial channels are present also in other cell compartments/membranes (for a tabulation see Ref. [40]). As far as is known, differences – if any - between the various populations of these channels are not such as to allow the development of small molecules specifically interacting with those residing in only one of multiple locations. In general, however, selective targeting of subcellular compartments – i.e., in our case, concentrating a drug at mitochondria - is desirable from various points of view (rev., e.g. Ref. [162]). Besides potentially reducing off-target effects and drug dosage, targeting mitochondria means exploiting their connection to cell death(s) and the peculiar roles the organelles have in cancer [2,40]. Selectively targeting mitochondrial channels is thus expected to maximize damage to cancer while minimizing damage to healthy cells.

The most popular strategy to address a “cargo” to mitochondria is to take advantage of the high transmembrane potential the organelles maintain. Positively charged, membrane-permeant objects (drugs, prodrugs, nanovesicles, markers, probes) will accumulate into mitochondria as they tend to reach electrochemical equilibrium. Since the plasma membrane of cells is also polarized, the cytoplasm serves as a “first stage” for the accumulation (roughly 10-fold), which can be as high as 1000-fold (theoretically even higher, depending on the value of the transmembrane potential) when comparing the mitochondrial matrix and the extracellular space. Mitochondria may be hyperpolarized in cancer cells [163–165], thus favouring the concentration of mitochondriotropic drugs in diseased cells and partially explaining the selectivity of their cytotoxic effect. The standard modification of a molecule to drive it into mitochondria consists in attaching to it a lipophilic (i.e., membrane-permeant) moiety carrying a permanent, delocalized charge. Since its invention by Skulachev and coworkers [166], and especially since its intelligent exploitation by Michael Murphy, Robin Smith and coworkers, triphenylphosphonium has been the most commonly used such group (reviews e.g. Refs. [167–171]).

A huge number of compounds have been modified by attachment of a TPP group, due to its efficiency and to the relative ease of introduction, generally by a nucleophilic substitution on a suitable precursor. In many cases this has been done with an eye to cancer therapy (revs: [165,168,172–175]). To cite just a few examples, this approach has been explored with polyphenols (e.g.: resveratrol and quercetin [176]; honokiol [177], lonicamide [178], glycyrrhetinic acid [179]; vitamin E succinate [180], the metal chelator desferrioxamine [181], metformin [182], topoisomerase blocker doxorubicin [183], the alkylating agent chlorambucil [184], microtubule-disrupting paclitaxel [185], Hsp90 inhibitors [186], platinum complexes [187], estrogen receptor modulator tamoxifen [188]. A particularly thorough study has been carried out with the tri-terpenoids betulin and betulinic acid [189]. The most noteworthy application may well be the development by Murphy’s group of the mitochondria-targeted antioxidant MitoQ(10), a ubiquinone derivative covalently attached to triphenylphosphonium through an aliphatic chain (optimally 10 methane units long) [190,191]. This compound has proven highly successful: a PubMed search for “MitoQ” returns 335 items (December 2020). Many studies have been carried out in in vivo models and in humans (e.g. Refs. [192,193]). MitoQ is mentioned in 19 entries in the clinical trials inventory (https://clinicaltrials.gov; December 2020). It has been suggested that it may be useful against Covid-19 [194]. Skulachev’s group has developed analogous compounds based on plastoquinones [195].

It should be pointed out that such modifications result in new molecules which may well have somewhat different properties – besides their preferential localization – with respect to the parent compounds. Thus, for example, they may have a decreased affinity for their targets (e.g. Ref. [180]), an issue not addressed in many studies. In addition, the length of alky spacer introduced to link the TPP group to the molecule core influences, e.g., the pharmacokinetics of betulin derivatives [179] and the behaviour of MitoQ [191].

Triphenylphosphonium has its drawbacks, the major one probably being its tendency to bind to biomembranes, a consequence of charge and of the lipophilicity which makes it such a serviceable tool (e.g. Ref. [196]). The charged moiety tends to associate with the negatively charged phospholipid headgroups, while the remaining part of the molecule, if sufficiently lipophilic, can insert into the membrane core. Binding is obviously also influenced by the specific properties of each derivative [181]. The accumulation of TPP-decorated molecules at the MIM and matrix may not only enhance their effectiveness at the mitochondrial level, but also limit other, possibly unwanted or confusing, interactions or processes in other cellular districts. This obviously applies to interactions with non-mitochondrial channels. Another example is provided by mito-targeted vitamin E succinate (mitoVES) a mitocan which efficiently kills cancer cells by ROS generation upon interaction with Complex II [180,197,198]. MitoVES reaches the mitochondria even in cancer cells that develop resistance to its untagged parent compound, VES, by upregulating the ATP-binding cassette transporter ABCA1 of the plasma membrane [199].

The bulky triphenylphosphonium group may also have an impact on the interaction of the active portion of the construct and its target protein. An example is again provided by mitoQ [10], which is a good substrate for Complex II of the mitochondrial respiratory chain, but not for Complexes I and III, for steric reasons [196]. The presence of TPP
may lead to unexpected effects: for example, just-mentioned mitoVES at sub-apoptotic doses suppressed expression of mitochondrial DNA transcripts, proliferation and mitochondrial biogenesis in cancer cells [200]. Its “parent” compound, α-tocopheryl succinate, did not produce the same effects.

A few papers have reported that some TPP-containing compounds, including some simple alkyl derivatives, can act as uncouplers and/or inhibitors of the respiratory chain (e.g. Refs. [182–184]). This is not a general behaviour exhibited by all such compounds, and, when present, can account in part for cytotoxic anti-cancer effects. TPP is not, in any case, the only possible choice for a mitochondria-targeting group. Other positive moieties, e.g. pyridinium, quinolinium and guanidine, have been tested (for review see Ref. [185]). As expected, mito-targeting generally increased the efficacy of the mitocans that were so modified, or actually created them.

3.2. Mitochondriotropic compounds targeting mitochondrial ion channels

Mitochondriotropic compounds targeting MOM or MIM channels are still only a few, all of them obtained by linking the parent drug to a TPP group. From the observations with psoralenic compounds (sect. 2.4) it was just a short logical step to mitochondrial ion channel derivatives of channel-modulating drugs. The two major variants produced had the TPP moiety linked to the PAP-1 core either by an alkoxo ether linkage, essentially stable under physiological conditions, or by a linker comprising a carbamate moiety, which could undergo hydrolysis and thus conferred pro-drug characteristics to the construct (Fig. 3C). These constructs proved effective – much more so than the parent PAP-1 – both in vitro and in vivo. Remarkably, they acted selectively on cancer cells, sparing normal cells and tissues. At the cellular level the details of their action were similar to those already observed for PAP-1: a transient increase of the mitochondrial transmembrane potential, production of reactive oxygen species (ROS), downstream mitochondrial depolarization and morphological changes - attributed to onset of the MPT on the basis of the effect of CSA, the established inhibitor of the latter - and cytochrome c release [201]. In vivo, both derivatives drastically reduced tumor growth in murine melanoma and PDAC models (about 80% and 60% reduction of endpoint tumor volume, respectively), even when administered alone at 5 nmol/mg bw in a straightforward protocol consisting in 4 alternate-day i. p. injections. About 90% melanoma volume reduction was achieved by administering PAPTP along with cisplatin, pointing to the possibility of synergy with other chemotherapeutic drugs. Indeed, one of the attractive features of these compounds is that they act independently of the upper part of the mitochondrial apoptotic cascade, i.e., regardless of the status of p53 and proteins of the Bcl-2 family [148,149,201]. ROS production was a key feature of the apoptotic cascade, i.e., regardless of the status of p53 and proteins of the Bcl-2 family [148,149,201]. ROS production was a key feature of the apoptotic cascade, i.e., regardless of the status of p53 and proteins of the Bcl-2 family [148,149,201]. Complex I inhibition is due to the oligoethyleneglycol side-arm of PAP-1-MHEG: without it, there was no inhibition; on the other hand, that portion of the molecule by itself was inert, even at high concentrations. Coherently, PAP-1 and PAPTP, which have no such appendage, do not inhibit Complex I. The interpretation is that the OEG chain must be appropriately positioned by virtue of the interaction of the rest of PAP-1-MHEG with Kv1.3, which is apposed to Complex I. A similar reasoning presumably applies to ROS generation: if the furocoumarin ring system was missing, the channel was inhibited but ROS production was relatively modest. On the other hand, 5-methoxypsoralene (5-MOP), i.e. the ring system without appendages, also induced only a comparatively weak production of ROS. It seems therefore that the psoralenic moiety must not only be present, but it must be appropriately positioned thanks to the interaction of the molecule with the mtKv1.3-complex I assembly. Our hypothesis is that its position overlaps that normally engaged by ubiquinone in the Q module of complex I [213,214], which is located in the portion of Complex I extending into the matrix. There, the aromatic, delocalized system could mediate an abnormal transfer of single electrons to oxygen, generating superoxide. Furocoumarins are known to engage in this type of redox chemistry [215] even though they are better known for photoinduced excitation and ionization.

The molecular details of these putative interactions and processes remain to be worked out, but some considerations can already be made. The modes of binding of PAP-1 to Kv1 channels have been defined in experimental and in silico studies [141,211,212]. The latter were based on the published structure of channel Kv1.2 [216], since that of Kv1.3 has not yet been determined and Kv1.2 is highly homologous. Zimin and co-workers [211] concluded that the channel is blocked by an assembly comprising two (but possibly up to four) PAP-1 molecules and a K+ ion, and their calculations detailed the mode of interaction of the terminal binding site and likely to interact with the various parts of the PAP-1 molecule. In the predicted structure, the two furocoumarins are located deep into the channel structure, making contact with their carbonyl moiety with a K+ ion in the conduit of the channel (which is what actually blocks the conduit), while the alkyphenoxyl side arms protrude towards the exterior between segments S5 and S6. This model accommodates the notion of an interaction of the oligoethyleneglycol chain with Complex I, but it is hardly compatible with the idea that the furocoumarin ring system
may reach out of the Kv1.3 tetramer. However, the molecular dynamics simulations conducted by Jorgensen et al. [212] led to the identification of a total of six possible binding sites for PAP-1 on the Kv1.2 tetramer. Of these, three seem to be the most often engaged: site II corresponds essentially to the inner site identified by Zimin et al.; site VI corresponds to a previously identified side-pocket accommodating small molecule inhibitors at the level of the S4–S5 linker; site III is located at the extremity of the channel structure protruding into the cytoplasm in the plasma membrane channel - and into the mitochondrial matrix in the mitochondrial one, which has the same in-out orientation [143]. Site III thus seems a likely candidate as an additional binding site for PAP-1 and derivatives, providing a foothold from which the molecule could conceivably extend towards Complex I. Importantly, according to the simulations by Jorgensen and colleagues, site III could accommodate either the psoralenic moiety or the phenoxyalkyl branch. Thus, in this picture, channel inhibition and ROS generation would depend on binding to two distinct sites. Obviously, even a low time-averaged occupation of the matrix site (site III) could in principle be sufficient to account for the extra ROS generation observed. The physiological functions, if any, fulfilled by this association between an ion channel and a complex of the respiratory chain remain to be investigated. It is however emerging that other mitochondrial channels also interact with key proteins of the oxphos system (see below).

Another mitochondrial-targeted inhibitor of a mitochondrial channel has been synthesized and is being tested in our labs (Bachmann M et al., in press). This is mitoIN-THPP (IsoNicopeptate-THPP) a 5,6,7,8-tetrahydrodropyrado[4,3-d]pyrimidine (THPP)-containing compound and an inhibitor of TASK-3 (Twik-related Acid-Sensitive K channel-3) (see above). The parent molecule is “12f” in Coburn et al., 2012 [217], which was reported to inhibit TASK-3 with an IC50 of 74 nM. The molecule contains in this case a hydrolysable ester linkage, and it may therefore be considered a mitochondriotropic pro-drug of IN-THPP. Indeed, cell esterases cleave the ester bond releasing IN-THPP-COOH. Both IN-THPP and mitoIN-THPP are cytotoxic for different human and mouse melanoma cells (which express TASK-3) in the tens-of-pM range, with the mitochondriotropic variant being more effective, by a factor of 2–4 in the various lines. Cytotoxicity depends on TASK-3 expression, and is associated with ROS production, mitochondrial depolarization, fragmentation of the mitochondrial network and decrease of cellular (ATP). These phenomena are not induced by the TPP-containing part of the molecule freed upon hydrolysis of the ester bond, and thus can be ascribed to the THPP part, and to TASK-3 inhibition (given the requirement for its expression). ATP decrease is associated with AMPK activation, which in turn is presumably involved in the decrease of migration capacity of melanoma cells, as measured by the wound scratch assay.

4. Modulation of cancer cell fate by peptides targeting mitochondrial ion channel interactions

Peptides (short sequences of amino acids, up to perhaps 30 monomers, found in nature or man-made) have been one of the most active fields of pharmacological research since at least the 1990’s. They attract interest because they are efficacious, versatile, and convenient. Their efficacy stems from their composition: they are made of the same building blocks as all proteins, and are therefore recognizable with relative ease by active or binding sites designed by co-evolution to interact with segments of proteins. Versatility follows from the huge number of variations available: if one considers the 20 standard (“L”) natural amino acids (a set that can be expanded by considering D isomers and a variety of unnatural amino acids), one can theoretically build 20N different sequences, where N is the number of monomeric units. Exploiting this variability and selecting the useful sequences is achieved by screening large random libraries selecting effective peptides thanks to phage [218,219], yeast [220], bacterial [221] and other forms of display/biopanning technology. Once an effective sequence is identified, it can be readily produced in the lab by the convenient, generally standard methods of solid phase peptide synthesis.

From a pharmacological point of view, there are two major ways to exploit this resource: one can use peptides to modulate pathophysiological processes, or to selectively deliver an attached “cargo” to a specific target. So-called mitochondria-penetrating peptides (e.g.Refs. [222,223]), a subfamily of cell-penetrating peptides [224,225], have in fact been used to deliver drugs to mitochondria, at least in vitro. For example, Kelley’s group coupled chlorambucil to a peptide consisting of three repeated doublets of cyclohexylphenylalanine and -arginine. The authors verified the mitochondrial localization of a version linked to a fluorescent dye, and were able to confirm the in vivo efficacy of the modified drug (although with mechanistic alterations) [184,226]. The same approach was used with doxorubicin [227]. Peptide-driven delivery to mitochondria has been discussed in recent reviews (e.g. Refs. [226,228]).

Many other functions aside, peptides can be immunomodulatory [229], impacting inflammation [230] and cancer [231]. In oncology, peptides are under consideration for anti-cancer vaccination (e.g. Refs. [229,232]) and chemotherapy (e.g. Refs. [233,234]). Peptide toxins are produced by all kingdoms of life, and several are used or are considered for use as drugs [235]. Some of these target mitochondria known to be present also in mitochondria. The best known are the high-affinity peptide inhibitors of K+ channels of the Kv, KCa, KFP families [235–238]. These peptides may help in the characterization of the various conductances found in the MIM, but they are not in use to modulate intracellular channels in cultured cells, ex-vivo preparations or in vivo, because they do not permeate cell membranes. The current state of pharmacological technology might well allow this obstacle to be overcome by including these toxins in constructs or nanovehicles comprising cell-penetrating and possibly mitochondria-targeting peptides. However the efficiency and selectivity of these targeting tools at present is not such as to eliminate off-target effects, which would be expected to be severe. Thus, there is to our knowledge no literature on the use of this class of peptides to module mitochondrial channels in a pathophysiological context.

4.1. Modulating VDAC1–hexokinase interaction with small peptides

It is however emerging that at least some mitochondrial ion channels interact, molecularly and functionally, with other components of the mitochondrial membranes or of the cellular milieu [138,210,239–241]. These interactions may in principle be disrupted via competition by appropriate peptides.

The foremost example of this strategy, as applied to mitochondrial channels in the context of cancer, involves VDAC1 (Fig. 2), the mitochondrial porin, whose expression, not coincidentally, is upregulated in many cancers [242]. Aerobic glycolysis, a hallmark of cancer, entails positioning of hexokinase I and II at the MOM, where it has immediate access to freshly produced ATP and can direct it to the production of glucose-6-phosphate [243,244]. Detachment of HKII results in cell death [245,246]. Hexokinase binds to VDAC1 and is preferentially localized at the junction complexes of mitochondria and endoplasmic reticulum (Mitochondria-Associated-Membranes; MAMs) [245,247]. In cancer cells up to 80% of HKII is found at MAMs. Its detachment precipitates cell death via activation of the permeability transition [245,246]. The N-terminal of HKII [248] (in particular His5 [249]) makes contact with VDAC1. In fact, peptides copying the N-terminal part competed with HKII for its binding site on VDAC1 and induced death of cancer cells [246] (Fig. 2). The sequence - MIASHLLAYFFTELN-amide (pHK) [248] – permeates cell membranes only poorly, and in most studies it has therefore been used as part of constructs comprising cell-penetrating sequences. Pastorino et al. [248] used the Antennipedia sequence (alias penetratin; their peptide is: RQIKIWFQNRRMKWKK-MIA HKII for its binding site on VDAC1 and induced death of cancer cells [245,246]. Hexokinase binds to VDAC1 and is preferentially localized at the junction complexes of mitochondria and endoplasmic reticulum (Mitochondria-Associated-Membranes; MAMs) [245,247]. In cancer cells up to 80% of HKII is found at MAMs. Its detachment precipitates cell death via activation of the permeability transition [245,246]. The N-terminal of HKII [248] (in particular His5 [249]) makes contact with VDAC1. In fact, peptides copying the N-terminal part competed with HKII for its binding site on VDAC1 and induced death of cancer cells [246] (Fig. 2). The sequence - MIASHLLAYFFTELN-amide (pHK) [248] – permeates cell membranes only poorly, and in most studies it has therefore been used as part of constructs comprising cell-penetrating sequences. Pastorino et al. [248] used the Antennipedia sequence (alias penetratin; their peptide is: RQIKIWFQNRRMKWKK-MIA HKII for its binding site on VDAC1 and induced death of cancer cells [245,246].
MIAHSLAYFFTELN[ΔA-GYGRKRRQRQRRG (TAT-HK)]. In their recent work Aihua Zou and coworkers fused pHK with the cell-penetrating sequence KVLQRRAKKKK and added a lipid chain to obtain amphiphilic nanostructures which could kill A549 cells, (a human non-small cell lung cancer line) at concentrations in the 10^{-5} M range [250]. Woldemariam et al. [251] instead covalently linked pHK to the penetrating sequence GKPILFF (PAS), obtaining analogous results with HeLa and CHO-K1 cells. A recent paper by Gisato and colleagues describes a peptide (HK2pep) comprising the pHK linked to a polycationic cell-penetrating-peptide shielded in turn by a polyamionic stretch with which it pairs up to minimize undesirable interactions. The two segments carrying opposite charges are connected by a sequence which can be cleaved by metallo matrix proteases (MMP) 2 and 9, characteristically abundant in many tumor types (HK2pep: MIAHSLAYFFTELN-LN-bA-RRRRRRRR-PLGLAG-Ahx-EEEEEEEE). Cleavage of the connecting sequence by these enzymes frees the active part of the molecule – cHKpep, i.e., pHK plus the cationic stretch (MIASHLLAYFFTELN-βI-RRRRRRRR-PLGLAG-Ahx-EEEEEEEE). Cleavage of the connecting sequence by these enzymes frees the active part of the molecule – cHKpep, i.e., pHK plus the cationic stretch (MIASHLLAYFFTELN–βI-RRRRRRRR-PLGLAG-Ahx-EEEEEEEE). Cleavage of the connecting sequence by these enzymes frees the active part of the molecule – cHKpep, i.e., pHK plus the cationic stretch (MIASHLLAYFFTELN–βI-RRRRRRRR-PLGLAG-Ahx-EEEEEEEE). Cleavage of the connecting sequence by these enzymes frees the active part of the molecule – cHKpep, i.e., pHK plus the cationic stretch (MIASHLLAYFFTELN–βI-RRRRRRRR-PLGLAG-Ahx-EEEEEEEE). Activation of this pathway appears to depend on a marked localization of HKII at MAMs. The cleaved construct was effective against B-CLL cells, and HK2pep worked upon injection into the tumoral mass in allograph models of colon and breast cancer expressing MMP2/9.

Various parts of VDAC1 participate in HK binding [248,252,253] (three cytosol-exposed glutamate residues, E72, E188, and E202 are crucial), which can nonetheless be disrupted also by peptides derived from VDAC1, in particular by a sequence containing E72 [254]. The interaction between VDAC1 and HK is modulated by GSK3β, which disrupts it by phosphorylating VDAC1 [255,256]. Activation of the kinase can thus be a strategy against cancer (e.g. Refs. [257,258]). Cyclophilin D, the already-mentioned mitochondrial matrix peptidyl-prolyl isomerase, upregulated in many cancers [259], which positively regulates the permeability transition [37,38], also stabilizes VDAC-HK interactions [260].

VDAC1 binds many other proteins of relevance in the oncological context (rev [261]) – including anti-apoptotic Bcl-2 and Bcl-xL, which are upregulated in many cancers and act to prevent chemotherapy-induced cell death. As is the case for VDAC1-HK binding, peptides based on VDAC1 sequences disrupt these interactions and have a pro-apoptotic effect (Fig. 2). Shoshan-Barmatz’s group has developed various forms of two peptides for this approach. In both cases the amino acids were, in most constructs, in the “unnatural” D configuration to enhance their stability and effectiveness. The D-N-Ter peptide based on the N-terminal sequence ([M]AVPPTYADGLGKSARDVFTKGYGFGL) was joined to the Antp sequence (KKWRMNQFWIKQR) because of the known involvement of the N-terminal of VDAC1 in binding these proteins. It interfered with HK, Bcl-2 and Bcl-xL binding and antagonized their anti-apoptotic effects [262,263]. The other peptide, named “LP4”, consisting of an N-terminal sequence SWTWE and a C-terminal sequence KWTWK, forms a tryptophan zipper and a β-hairpin. This peptide was fused either to Antp (RQIKIWFQNRRMKWKK) or to the L-chain receptor (TIR)-recognizing peptide HAIPRH [264], with the amino acids in either the L or D configuration [265,266]. Various modifications of these constructs were also implemented. The peptides entered cells and induced detachment of the target proteins from VDAC1. They were tested on the targets of metastatic breast cancer, lung cancer, lymphoma, leukemia, and lymphoblastomas. As a result, the peptides caused apoptosis in cancer cell lines, and the VDAC/HK interactions were antagonized in vivo. This indicates that the VDAC/HK interactions may be very useful to drive cancer cells towards death. In this respect it is interesting to note that basically every respiratory chain complex was shown to be physiologically (and possibly functionally) coupled to various ion channels. Whether such association is compulsory for cell survival is still unknown.

In terms of future perspectives, hopefully mitochondrial ion channels will become preferred targets of various groups working on cancer. Clinical trials involving betulinic acid, noscapine and honokiol (activators of the MPTP), mitoxantrone (MUCI inhibitor), cannabidiol, are referred to in the text (sect. 2). Other compounds mentioned, e.g. capsaicin and kaempferol, are employed in clinical trials, but not as chemotherapeutic agents. Difficulties in crossing biomembranes (requiring fusion with permeating peptides; sect. 4.1), rapid proteolytic degradation in vivo (requiring the use of “tricks” such as the incorporation of D-aminoacids or packaging in nanovehicles) and relatively high costs presumably account for the lack of clinical trials employing peptides targeting the interactions of VDAC with hexokinase or anti-apoptotic proteins. Unfortunately, to date none of the mitochondrial ion channel-modulators have reached the clinical trial phase, as to our knowledge large-scale toxicity studies have not been performed yet. Further developments in the field of mitochondrial ion channel modulators may envision a way to activate drug/peptide-channel interaction through events triggered by e.g. tumor-directed gamma-radiation used in radiotherapy or hypoxic conditions prevailing inside solid tumors.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We are grateful to all colleagues who participated in the works performed in our laboratories and we thank all our external collaborators. We also thank for the continuous support the Italian Association for Cancer Research (IG 2017, Id.20286), the Italian Association for Multiple Sclerosis FISM/AISM (Prot. 284/18/F14) and the CNR InterOmics
I. Szabo et al. - Redox Biology 42 (2021) 101846

References

[1] D. Grasso, L.X. Zampieri, T. Capeloa, J.A. Van de Velde, P. Sonveaux, Mitochondria in cancer therapy, Cell Mol. Life Sci. 4 (6) (2020) 114-146.
[2] K.G. Roth, I. Mambetsarieva, P. Kulkarni, R. Salgia, The mitochondrial as an emerging therapeutic target in cancer, Trends Mol. Med. 26 (1) (2020) 119-134.
[3] R. Peruzzo, R. Costa, M. Bachmann, L. Leanza, I. Szabo, Mitochondrial metabolism, contact sites and cellular calcium signaling: implications for tumorigenesis, Cancers 12 (9) (2020).
[4] K. Vasan, M. Werner, N.S. Chandel, Mitochondrial metabolism as a target for cancer therapy, Cell Metab. 32 (3) (2020) 341-352.
[5] J. Nakhte, A.M. Reddy, M.L. Vignati, C. Jankovic, Mitochondrial roles of mitochondrial components and metabolites in metabolic diseases and cancer, Int. J. Mol. Sci. 21 (12) (2020).
[6] I. Szabo, M. Zoratti, Mitochondrial channels: ion fluxes and more, Physiol. Rev. 94 (2) (2014) 519-608.
[7] V. Shohan-Barmatz, V. De Pinto, M. Zweckstetter, Z. Raviv, N. Keinan, N. Arbel, VDAC, a multi-functional mitochondrial protein regulating cell life and death, Mol. Aspect Med. 31 (3) (2010) 227-285.
[8] S. Naghdi, G. Hajnoczy, VDAC2-specific cellular functions and the underlying structure, Biochim. Biophys. Acta 1863 (10) (2016) 2503-2514.
[9] D. Malinska, S.R. Mirandola, W.S. Kunz, Mitochondrial potassium channels and regulation of oxygen species, FEBS Lett. 584 (10) (2020) 2043-2048.
[10] M. Hornsveld, T.B. Dansen, The hallmarks of cancer from a redox perspective, Antioxidants Redox Signal. 25 (6) (2016) 300-325.
[11] I. Lippolito, E. Giannoni, P. Chiarugi, M. Parri, Mitochondrial redox hubs as promising targets for anticancer therapy, Frontiers in oncology 10 (2020) 256.
[12] J. Robehna, L.F. Dong, S.J. Ralph, J. Neuzil, Anticancer drugs targeting the mitochondrial electron transport chain, Antioxidants Redox Signal. 15 (12) (2011) 2951-2974.
[13] J. Neuzil, E. Gyorke, J. Robehna, J. Truksa, S.J. Ralph, Classification of mitocans, anti-cancer drugs acting on mitochondria, Mitochondrion 13 (3) (2013) 199-208.
[14] C. Nguyen, S. Pandey, Exploiting mitochondrial vulnerabilities to trigger apoptosis selectively in cancer cells, Cancers 11 (7) (2019).
[15] L. Biasutto, L.I. Dong, M. Zoratti, J. Neuzil, Mitochondrial targeted anti-cancer agents, Mitochondrion 10 (6) (2010) 670-681.
[16] S.J. Ralph, S. Rodriguez-Enriquez, J. Neuzil, R. Moreno-Sanchez, Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger, Mol. Aspet Med. 31 (1) (2010) 29-59.
[17] J.S. Modica-Napolitano, V. Weissig, Treatment strategies that enhance the inner membrane permeability transition in liver mitochondria, J. Biol. Chem. 264 (14) (1989) 7826-7830.
[18] M. Crompton, H. Ellinger, A. Costi, Inhibition by cyclosporin A of a Ca2+ -dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress, Biochem. J. 255 (1) (1988) 357-360.
[19] L. Leanza, V. Chechletto, L. Biasutto, A. Rossa, R. Costa, M. Bachmann, et al., Pharmacological modulation of mitochondrial ion channels, Br. J. Pharmacol. 176 (18) (2018) 4258-4283.
[20] S. Parrassia, A. Mattarei, A. Furlan, M. Zoratti, L. Biasutto, Small-molecule modulators of mitochondrial channels as chemotherapeutic agents, Chem. Physiol. Biochem.: international journal of experimental cellular physiology, biochemistry, and pharmacology, 95 (53) (2019) 11-43.
[21] C. Chinopoulou, Mitochondrial permeability transition pore: back to the drawing board, Neurochem. Int. 117 (2019) 48-54.
[22] V. Giorgio, S. von Stockum, M. Antoniel, A. Fabbro, F. Fogliaroli, M. Forte, et al., Doxorubicin modulates the formation of the mitochondrial permeability transition pore, Proc. Natl. Acad. Sci. U.S.A. 110 (15) (2013) 5887-5892.
[23] A. Urbani, V. Giorgio, A. Carrer, C. Franchin, G. Arrigoni, C. Jiko, et al., Purified F-ATP synthase forms a Ca2+-dependent high-conductance channel matching the mitochondrial permeability transition pore, Nat. Commun. 10 (1) (2019) 4341.
[24] N. Mnatsakanyan, H.-A. Park, W. Jing, M.C. Llaguno, B. Murthi, M. Latta, et al., Mitochondrial megachannel resides in monomeric ATP synthase, Biochem. J. 416 (1) (2019) 156a.
[25] C. Gerle, Mitochondrial F-ATP synthase as the permeability transition pore, Pharm. Res. 160 (2020) 105081.
[26] G. Piizka, L. Zhou, L.A. Szanosz, Cryo-EM structure of the entire mammalian F-type ATP synthase, Nat. Struct. Mol. Biol. 27 (11) (2020) 1077-1085.
[27] C. Nardon, F. Chiara, L. Brustolin, A. Gambalunga, F. Ciscato, A. Rasola, et al., Chemotherapeutic induction of mitochondrial oxidative stress activates GSK-3a/b and Bax, leading to permeability transition pore opening and tumor cell death, Cell Death Dis. 11 (2020) 1-94.
[28] A. Hordyjewska, A. Ostapiuk, A. Horecka, J. Kurzepa, Betulin and betulinic acid: triterpenoid derivatives with a powerful biological potential, Phytochemistry Rev. 18 (3) (2019) 929-951.
[29] S.S. Bellampalli, Y.J. A, Moutai, S.A. Cui, E.M.K. Jwieratne, M.A. Gandelini, et al., Betulinic acid, derived from the desert lavender Hypsic eris emoryi, attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy through inhibition of N- and T-type calcium channels, Pain 160 (1) (2017) 113-117.
[30] A.M.L. Seca, D. Pinto, Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application, Int. J. Mol. Sci. 19 (1) (2018).
[31] E. Pisha, H. Chai, I.S. Lee, T.E. Chagwedera, N.R. Farnsworth, G.A. Cordell, et al., Targeting mitochondria as an emerging therapeutic strategy, Nat. Rev. Drug Discov. 18 (3) (2019) 134-150.
[32] X. Yuan, P. Wang, T. Zhang, W. Zhang, Betulinic acid, derived from the desert lavender Hypsic eris emoryi, attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy through inhibition of N- and T-type calcium channels, Pain 160 (1) (2017) 113-117.
[33] E. Pisha, H. Chai, I.S. Lee, T.E. Chagwedera, N.R. Farnsworth, G.A. Cordell, et al., Targeting mitochondria as an emerging therapeutic strategy, Nat. Rev. Drug Discov. 18 (3) (2019) 134-150.
[34] A.M.L. Seca, D. Pinto, Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application, Int. J. Mol. Sci. 19 (1) (2018).
[35] E. Pisha, H. Chai, I.S. Lee, T.E. Chagwedera, N.R. Farnsworth, G.A. Cordell, et al., Targeting mitochondria as an emerging therapeutic strategy, Nat. Rev. Drug Discov. 18 (3) (2019) 134-150.
[36] A.M.L. Seca, D. Pinto, Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application, Int. J. Mol. Sci. 19 (1) (2018).
[37] E. Pisha, H. Chai, I.S. Lee, T.E. Chagwedera, N.R. Farnsworth, G.A. Cordell, et al., Targeting mitochondria as an emerging therapeutic strategy, Nat. Rev. Drug Discov. 18 (3) (2019) 134-150.
mitochondria: the hyperpolarization-activated and cyclic nucleotide-gated HCN channels, Int. J. Mol. Sci. 20 (20) (2019), 7340.
[139] A. Wrzosek, B. Augustynek, M. Zorzella, A. Szewczyk, Mitochondrial potassium channels as druggable targets, Biomolecules 10 (8) (2020).
[140] J. Vennekamp, H. Wulff, C. Beeton, P.A. Calabrese, S. Grissmer, W. Hansel, et al., Kv1.3-blocking 5-phenylalkoxypropions: a new class of immunomodulators, Mol. Cancer Ther. 15 (6) (2016) 1287–1297.
[141] S.B. Bodendiek, M. Hauser, H. Wulff, H. Wulff, 4-Phe noxybutyric acid-substituted heterocycles—a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3, Eur. J. Med. Chem. 44 (5) (2009) 1838–1852.
[142] K.G. Chandy, H. Wulff, C. Beeton, M. Pennington, G.A. Gunter, M.D. Cahalan, K+ channels as targets for specific immunomodulation, Trends Pharmacol. Sci. 25 (5) (2004) 280–289.
[143] L. Sasso, J. Bock, H. Grasme, M. Soddenmann, B. Willer, F. Lang, et al., Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes, Proc. Natl. Acad. Sci. U.S.A. 105 (39) (2008) 14861–14866.
[144] L. Sasso, M. Soddenmann, A. Zoratti, E. Gulbins, Single-point mutations of a lysine residue change function of Bax and Bcl-2, expressed in Bax- and Bak- less mouse embryonic fibroblasts novel insights into the molecular mechanisms of Bax-induced apoptosis, Cell Death Differ. 18 (3) (2011) 427–438.
[145] L. Leanza, P. O'Reilly, A. Doyle, E. Venturini, M. Zoratti, E. Szegedi, et al., Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines, Curr. Pharmaceut. Des. 20 (2) (2014) 189–200.
[146] V.B. Ben, F. Fan, S. Parve, A. Fleig, C.R. Chong, J. Xu, et al., Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes, PloS One 6 (12) (2011), e28287.
[147] M.F. van Delft, S. Chappaz, Y. Khakham, C.T. Bui, M.A. Debrincat, K.N. Lowes, et al., H. Huang, K. Shah, N.A. Bradbury, C. Li, C. White, Mcl-1 promotes lung cancer cell migration by directly interacting with VDAC to increase mitochondrial Ca2+ uptake and reactive oxygen species generation, Cell Death Dis. 5 (2014) e1482.
[148] M. Bachmann, G. Pontarin, L. Sasso, The contribution of mitochondrial potassium anion channel is coupled to the induction of apoptosis, Mol. Cell. Biol. 30 (24) (2010) 5698–5709.
[149] V. Haridas, X. Li, T. Mizumachi, M. Higuchi, V.V. Lemanenko, M. Colombini, et al., A novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane, Mitochondrion 7 (3) (2007) 234–240.
[150] H. Wang, V. Haridas, Gutierrez J.M., Z.X. Yu, Natural triterpenoid avicins selectively induce tumor cell death, Commun. Integr. Biol. 3 (5) (2010) 205–208.
[151] P. Massi, M. Solinas, V. Cincinna, D. Parolaro, Cannabidiol as potential anticancer drug, Br. J. Clin. Pharmacol. 75 (2) (2013) 303–312.
[152] N. Rimmerman, L. Mazur, Z. Porat, A. Juknat, E. Kozela, M.P. Daniels, et al., Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death, Cell Death Dis. 4 (12) (2013) e494.
[153] D. Tesarvi, T. Ahm, V.R. Chira, P.K. Chirakali, P.K. Sri, J.P. Srivastava, et al., Manipulation of the mitochondrial voltage dependent anion channel (VDAC) by curcumin, Biochem. Biophys. Acta 1848 (1 Pt A) (2015) 151–158.
[154] Q. Li, P. Qiao, X. Chen, J. Wang, L. Bian, X. Zheng, Affinity chromatographic methodologies based on immobilized voltage-dependent anion channel inform 1 and application in protein-ligand interaction analysis and bioactive compounds screening from traditional medicine, J. Chromatography. A 1495 (2017) 31–45.
[155] L. Sasso, J. Bock, A. Jelke, M. Soddenmann, C. Adams, F. Lang, et al., A novel potassium channel in lymphocyte mitochondria, J. Biol. Chem. 280 (13) (2005) 12790–12798.
[156] L. Leanza, M. Zoratti, E. Gulbins, I. Sasso, Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels, Curr. Med. Chem. 19 (21) (2012) 5394–5404.
[157] L. Testa, V. Barrese, M.V. Soldovieri, P. Ambrosino, A. Martelli, I. Vinciguerra, et al., Expression and function of Kv7.4 channels in Rat cardiac mitochondria: possible targets for cardiprotection, Cardiovasc. Res. 110 (1) (2016) 40–50.
[158] A.M. Dolgo, M.F. Nettet, F. Perrochi, N. Doti, L. Meiners, S. Tobaben, et al., Mitochondrial small conductance SK2 channels prevent glutamate-induced oxygen and mitochondrial dysfunction, J. Biol. Chem. 288 (15) (2013) 10792–10804.
[159] U. De Marchi, N. Sassi, B. Fioretti, L. Catarcuzzeno, G.M. Cereghetti, I. Szabo, et al., Intermediate conductance Ca2+-activated K+ channels in the cardiac inner mitochondrial membrane, Science 298 (5959) (2002) 1029–1033.
[160] A.J. Kowalski, S. Serhbanaran, P. Pucek, K.D. Garlid, Bioenergetic consequences of opening the ATP-sensitive K(+) channel of heart mitochondria, Am. J. Physiol. Heart Circ. Physiol. 280 (2) (2001) H649–H657.
[161] A. Paggio, V. Cecchetto, A. Campo, R. Menabio, G. Di Marco, F. Di Lisa, et al., Identification of an ATP-sensitive potassium channel in mitochondria, Nature 572 (7771) (2019) 609–613.
[162] D.B. Foster, A.S. Ho, J. Rucker, A.O. Garlid, L. Chen, A. Sider, et al., Mitochondrial ROMK channel is a molecular component of mitoK(ATP), Circ. Res. 113 (4) (2018) 460–466.
[163] M. Laskowski, B. Augustynek, P. Bednarczyk, M. Zorzella, J. Kalisz, B. O’Rourke, et al., Single-channel properties of the ROMK-pore-forming subunit of the mitochondrial ATP-sensitive potassium channel, Int. J. Mol. Sci. 20 (21) (2019).
[164] R. Toczyłowska-Mamiska, A. Olszewska, M. Laskowski, P. Bednarczyk, K. Skworek, A. Szewczyk, Potassium channel in the mitochondria of human keratinocytes, J. Invest. Dermatol. 134 (3) (2014) 764–772.
[165] Z. Ruznak, G. Bakódí, L. Kozák, K. Pocius, B. Danes, J. Fedor, et al., Mitochondrial expression of the two-domain TASK-3 channels in malignantly transformed and non-malignant human cells, Virchows Arch. : an international journal of experimental cellular pathology, biochemistry, and pharmacology 53 (SI) (2019) 63–78.
[166] A.F. Wójcik, T.A. Sherman, S.M. Nadtochy, W.R. Ursu, P.S. Brooks, K. Neheze, SLO-2 is cytoprotective and contributes to mitochondrial potassium transport, PloS One 6 (2) (2011), e28287.
[167] D. León-Aparicio, J. Rodríguez-Orellana, O.E. Aparicio-Trejo, A. Briones-Herrera, J. Pedro-Chávez, L. Vaca, et al., Novel potassium channels in kidney
Mitochondria-targeted triphenylphosphonium analogues of betulin.

Z. Zhu, Z. Wang, C. Zhang, Y. Wang, H. Zhang, Z. Gan, et al., Mitochondrion.

Z. Zhang, M. Banerjee, R.E. Davis, B.S.J. Blagg, Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity, Bioorg. Med. Chem. Lett. 18 (9) (2008) 2546–2550.

L. Jin, L. Dai, M. Ji, H. Wang, Mitochondria-targeted triphenylphosphonium conjugated glycuronic acid derivatives as potent anticancer drugs, Bioorg. Chem. 85 (2019) 179–190.

L.F. Dong, V.J. Jameson, D. Tilly, J. Cerny, E. Mahdavian, A. Marin-Hernández, et al., Mitochondria-targeted ubiquinone: a potential treatment for mitochondrial superoxide production by reverse electron transport at complex I, Frontiers in oncology 8 (2018) 122.

P. Kovalčík, L. Procházka, S. Koudelka, L.F. Dong, J. Stursa, J. Goodwin, J. Neca, et al., Structural and functional changes in complex I may contribute to the impairment of the proton gradient in cancer cells, Biochim. Biophys. Acta 1817 (7) (2012) 1095–1106.

S. Rodríguez-Enríquez, L. Hernández-Enríquez, A. Marín-Hernández, L. Ouyang, J. Gong, Mitochondrial-targeted ubiquinone: a potential treatment for mitochondrial superoxide production by reverse electron transport at complex I, Frontiers in oncology 8 (2018) 122.

S.S. Korshunov, V.P. Skulachev, A.A. Starkov, High protonic potential actuates a mitochondrial superoxide dismutase, Biochemistry 41 (41) (1992) 13342–13346.

L. Leanza, M. Romio, K.A. Becker, M. Azzolini, L. Trentin, A. Manago, et al., Insights into the mechanism of the mitochondrial complex I channel selectively kills tumor cells in vivo, Cell. Physiol. Biochem.: international journal of experimental cellular physiology, biochemistry, and pharmacology 53 (5) (2019) 1–10.

N. Sassi, L. Biasutti, A. Mattarei, M. Carraro, V. Giorgio, A. Citta, et al., Targeting the potassium channel Kv1.3 kills glioblastoma cells, Neurosignals 25 (1) (2017) 26–38.

I. Szabó et al., Novel mitochondria-targeted furocoumarin derivatives as possible anti-cancer agents, Frontiers in oncology 8 (2018) 122.

S.K. Korshunov, V.P. Skulachev, A.A. Starkov, High protonic potential actuates a mitochondrial superoxide dismutase, Biochemistry 41 (41) (1992) 13342–13346.

D.B. Zorov, M. Juhaszova, S.J. Sollott, Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release, Physiol. Rev. 94 (3) (2014) 909–950.

S.S. Korshunov, V.P. Skulachev, A.A. Starkov, High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria, FEBS Lett. 416 (1) (1997) 15–18.

B. Kadenbach, R. Ramzan, S. Vogt, High efficiency versus maximal performance—the cause of oxidative stress in erythropoiesis: a hypothesis, Acta biologica and medicina 13 (1) (2001) 45–49.

E.L. Robb, A.R. Hall, T.A. Prime, S. Eaton, M. Szibor, C. Viscomi, et al., Control of mitochondrial superoxide production by reverse electron transport at complex I, J. Biol. Chem. 293 (25) (2018) 9869–9879.

R. Peruzzo, A. Mattarei, M. Azzolini, K.A. Becker-Flegler, M. Romio, G. Rigoni, et al., Insights into the mechanism of cytotoxicity of membrane-permeant porosarcin Kv1.3 channel inhibitors by chemical dissection of a novel member of the family, Redox biology 37 (2020) 101705.

P.I. Zimin, B. García, S.B. Bodenrick, C. Mähieux, H. Wulf, B.S. Zhavor, Mitochondria-targeted flavonoids to improve gene expression in cancer cells, Acta biologica and medicina 13 (1) (2001) 45–49.

B. Kadenbach, R. Ramzan, S. Vogt, High efficiency versus maximal performance—the cause of oxidative stress in erythropoiesis: a hypothesis, Acta biologica and medicina 13 (1) (2001) 45–49.

E.L. Robb, A.R. Hall, T.A. Prime, S. Eaton, M. Szibor, C. Viscomi, et al., Control of mitochondrial superoxide production by reverse electron transport at complex I, J. Biol. Chem. 293 (25) (2018) 9869–9879.

R. Peruzzo, A. Mattarei, M. Azzolini, K.A. Becker-Flegler, M. Romio, G. Rigoni, et al., Insights into the mechanism of cytotoxicity of membrane-permeant porosarcin Kv1.3 channel inhibitors by chemical dissection of a novel member of the family, Redox biology 37 (2020) 101705.

P.I. Zimin, B. García, S.B. Bodenrick, C. Mähieux, H. Wulf, B.S. Zhavor, Mitochondria-targeted flavonoids to improve gene expression in cancer cells, Acta biologica and medicina 13 (1) (2001) 45–49.

B. Kadenbach, R. Ramzan, S. Vogt, High efficiency versus maximal performance—the cause of oxidative stress in erythropoiesis: a hypothesis, Acta biologica and medicina 13 (1) (2001) 45–49.

E.L. Robb, A.R. Hall, T.A. Prime, S. Eaton, M. Szibor, C. Viscomi, et al., Control of mitochondrial superoxide production by reverse electron transport at complex I, J. Biol. Chem. 293 (25) (2018) 9869–9879.

R. Peruzzo, A. Mattarei, M. Azzolini, K.A. Becker-Flegler, M. Romio, G. Rigoni, et al., Insights into the mechanism of cytotoxicity of membrane-permeant porosarcin Kv1.3 channel inhibitors by chemical dissection of a novel member of the family, Redox biology 37 (2020) 101705.
V. Shoshan-Barmatz, D. Ben-Hail, L. Admoni, Y. Krelin, S.S. Tripathi, et al., Mitochondrial VDAC1-based peptides: attacking oncogenic properties in cancer cells, Front. Pharmacol. 11 (2020) 913.

J.G. Pastorino, J.B. Hoek, N. Shulga, Activation of glycolysis synthase kinase 3βeta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity, Oncogene. 35 (20) (2016) 2701–2708.

J.G. Pastorino, J.B. Hoek, Regulation of hexokinase binding to VDAC, J. Bioenerg. Biomembr. 40 (3) (2008) 171–182.

Y. Guo, L. Wei, Y. Zhou, N. Lu, X. Tang, Z. Li, et al., Flavonoid GL-V9 induces apoptosis and inhibits glycolysis of breast cancer via disrupting GSK-3β-mediated mitochondrial binding of HKII, Free Radic. Biol. Med. 146 (2020) 119–129.

Y.N. Xue, B.B. Yu, J.L. Li, R. Guo, L.C. Zhang, L.K. Sun, et al., Zinc and p53 disrupt mitochondrial binding of HK2 by phosphorylating VDAC1, Exp. Cell Res. 374 (1) (2019) 249–258.

A. Bigi, E. Beltrami, M. Trinei, M. Stendardo, P.G. Pellici, M. Giorgio, Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis, Oncogene. 35 (39) (2016) 5132–5143.

K. Machida, Y. Ohta, H. Osada, Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells, J. Biol. Chem. 281 (20) (2006) 14314–14320.

V. Shoshan-Barmatz, Y. Krelin, Q. Chen, VDAC1 as a player in mitochondria-mediated apoptosis and target for modulating apoptosis, Curr. Med. Chem. 24 (40) (2017) 4435–4446.

L. Arrozín, N. Zilberberg, R. Ben-Romano, V. Shoshan-Barmatz, Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity, J. Biol. Chem. 284 (6) (2009) 3946–3955.

N. Arbel, V. Shoshan-Barmatz, Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity, J. Biol. Chem. 285 (9) (2010) 6053–6062.

J.H. Lee, J.A. Engler, J.F. Collawn, B.A. Moore, Receptor mediated uptake of chemical probes and therapeutics to mitochondria, Acc. Chem. Res. 49 (13) (2016) 2581–2589.

J.F. Collawn, B.A. Moore, Development of novel peptides for cell-penetrating peptide targets mitochondria and triggers apoptosis in cancer cells, Faseb. J.; official publication of the Federation of American Societies for Experimental Biology 31 (5) (2017) 2168–2184.

S. Abu-Hamad, H. Zaid, A. Isrealon, E. Nahon, V. Shoshan-Barmatz, Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: mapping the site of binding, J. Biol. Chem. 283 (19) (2008) 13482–13490.

V. Shoshan-Barmatz, M. Zakar, K. Rosenthal, S. Abu-Hamad, Key regions of VDAC1 functioning in apoptosis induction and regulation by hexokinase, Biochem. Biophys. Acta 1797 (5) (2009) 421–430.

J.A. Al Jamal, Involvement of porin N,N-dicyclohexylcarbodiimide-reactive domain in hexokinase binding to the outer mitochondrial membrane, Protein J. 24 (1) (2005) 1–8.

J.G. Pastorino, J.B. Hoek, N. Shulga, Activation of glycolysis synthase kinase 3βeta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity, Oncogene. 35 (20) (2016) 5132–5143.

J.G. Pastorino, J.B. Hoek, Expression and function of voltage-dependent anion channel isoforms, Mol. Biosyst. 13 (40) (2017) 4435–4446.

T. Prezma, A. Shteinfer, L. Admoni, Z. Raviv, I. Sela, et al., VDAC1-based peptides in cancer treatment, Curr. Protein Pept. Sci. 19 (8) (2018) 759–776.

J. Herzig, B. Cristofori-Armstrong, M.R. Israel, S.A. Nixon, I. Vetter, G.F. King, M.R. Israel, S.A. Nixon, I. Vetter, G.F. King, Voltage-gated K+-dependent death of cancer cells, EMBO Rep. 21 (7) (2020), e49117.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.

S.O. Kelley, K.M. Stewart, R. Mourtada, Development of novel peptides for multi-cargo intracellular carriers, Expet Opin. Drug Deliv. 16 (11) (2019) 1257–1270.